HSF1 and breast carcinoma: We then treated CGL2 (Fig. 6a) or MDA-MB-231 breast cancer cells (Fig. 6b) with each anti-mitotic drug plus the indicated HSF1 inhibitor and found that the combined treatment significantly reduced the cell viability compared to anti-mitosis drug alone or HSF1 inhibitor alone (Fig. 6).